Table 2.
Patients characteristics according to their graft sources
| HLA-mismatched grafts recipients (n=345) | Umbilical cord blood grafts recipients (n=262) | Haploidentical grafts recipients (n=117) | |
|---|---|---|---|
| Conditioning (%) | |||
| High-dose | 66 | 55 | 3 |
| Nonmyeloablative/reduced-intensity conditioning | 35 | 45 | 97 |
| ATG use | 4 | 18 | 0 |
| Age, median (range) | 45 (0.6–76) | 37 (0.4–73) | 37 (0.5–74) |
| < 40 | 37 | 61 | 45 |
| ≥ 40 | 63 | 39 | 55 |
| Disease risk (%) | |||
| Low | 39 | 49 | 34 |
| High | 61 | 51 | 66 |
| Cytomegalovirus status | |||
| Negative | 43 | 40 | 32 |
| Positive | 57 | 60 | 68 |
| Donor type (%) | |||
| Related | 13 | 100 | |
| Unrelated | 87 | 100 | |
| Stem cells source (%) | |||
| Peripheral blood stem cells | 73 | 80 | |
| Bone marrow | 27 | 20 | |
| Umbilical cord blood | — | 100 | — |
| Single unit | — | 42 | — |
| Two units | — | 58 | — |
| Augmented comorbidity/age index (%) | |||
| <4 | 48 | 52 | 43 |
| ≥ 4 | 52 | 48 | 57 |
| Median (range) | 4 (0–14) | 3 (0–13) | 4 (0–14) |
| Karnofsky performance status score (%) | |||
| > 80 | 88 | 89 | 81 |
| ≤ 80 | 13 | 11 | 19 |
| Year of transplant (%) | |||
| 2000 to 2004 | 43 | 6 | 14 |
| 2005 to 2009 | 38 | 40 | 45 |
| 2010 to 2010 | 29 | 55 | 41 |
| Follow-up of surviving patients, years | |||
| Median (range) | 8.0 (1.2–16.1) | 4.1 (1.7–12.9) | 5.0 (0.2–11.4) |
1
missing for 1 HLA-mismatched recipient and 6 cord blood recipients
HCT-CI = Hematopoietic Cell Transplantation-specific Comorbidity Index.